Antibody-drug conjugates (ADCs) combine the strong cytotoxicity of small molecule drugs with the selectivity of monoclonal antibodies and exhibited good pharmacokinetic characteristics, making them very promising drugs for the treatment of HER2-positive cancers. This evidence concerns the gene ERBB2 and cancer.